ReviewMedical gas research2026
Plasma-activated gas: a new dawn for wound care and infection.
Review in Medical gas research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasma-activated gas, an emerging technology derived from non-thermal plasma, demonstrates considerable promise in wound management through its rich repertoire of reactive oxygen and nitrogen species. Plasma-activated gas exerts broad-spectrum antimicrobial activity through multi-target mechanisms, effectively eliminating multidrug-resistant pathogens, including methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa , as well as disrupting bacterial biofilm architecture. In tissue repair, plasma-activated gas orchestrates the entire wound healing cascade. It accelerates platelet activation and coagulation, enhances proliferation and migration of epithelial cells and fibroblasts by activating vascular endothelial growth factor receptor-extracellular regulated protein kinases 1/2 and transforming growth factor-β/Smad signaling pathways, promotes angiogenesis via the endothelial nitric oxide synthase-vascular endothelial growth factor axis, and optimizes tissue remodeling by fine-tuning the matrix metalloproteinases and their tissue inhibitors balance. Preclinical and early clinical studies confirm that plasma-activated gas significantly shortens healing time, mitigates scar formation, and effectively controls wound infection. Although challenges remain in standardization, safety profiling, and clinical translation, advances in precise dosing strategies and intelligent device design position plasma-activated gas as a transformative approach for managing refractory chronic wounds. The results and cutting-edge advancements summarized in this review are expected to provide a valuable and forward-looking reference for the subsequent research and development upgrading and clinical translational application of plasma-activated gas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.